KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Long-Term Investments (2018 - 2019)

Historic Long-Term Investments for Esperion Therapeutics (ESPR) over the last 2 years, with Q1 2019 value amounting to $30.9 million.

  • Esperion Therapeutics' Long-Term Investments fell 2704.6% to $30.9 million in Q1 2019 from the same period last year, while for Mar 2019 it was $30.9 million, marking a year-over-year decrease of 2704.6%. This contributed to the annual value of $243000.0 for FY2018, which is N/A changed from last year.
  • Per Esperion Therapeutics' latest filing, its Long-Term Investments stood at $30.9 million for Q1 2019, which was down 2704.6% from $243000.0 recorded in Q4 2018.
  • Over the past 5 years, Esperion Therapeutics' Long-Term Investments peaked at $42.4 million during Q1 2018, and registered a low of $243000.0 during Q4 2018.